EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis —Long-Term, Open-Label Study to Enroll Approximately 3,000 Patients Across Europe— …
Raising Awareness of Primary Ciliary Dyskinesia this Rare Disease Day! 🌍 Today is #RareDiseaseDay and to celebrate we are raising awareness of Primary Ciliary Dyskinesia (PCD)!💙 PCD is a …
Professor James Chalmers to join the Radcliffe Department of Medicine We are delighted to announce that Professor James Chalmers has been recruited to the statutory Rhodes Professorship of Experimental Therapeutics …
Clinical Trial led by EMBARC Reveals Potential of Novel Antibody Therapy against Pseudomonas in Patients with Bronchiectasis – Results of the GREAT-2 Study Research Highlights Proof of concept study achieves …
A breakthrough for bronchiectasis: the results of the Phase III ASPEN trial are published On April 23rd, 2025, the long-awaited results of the Phase III ASPEN trial of Brensocatib for …
/*! elementor – v3.22.0 – 26-06-2024 */ .elementor-heading-title{padding:0;margin:0;line-height:1}.elementor-widget-heading .elementor-heading-title[class*=elementor-size-]>a{color:inherit;font-size:inherit;line-height:inherit}.elementor-widget-heading .elementor-heading-title.elementor-size-small{font-size:15px}.elementor-widget-heading .elementor-heading-title.elementor-size-medium{font-size:19px}.elementor-widget-heading .elementor-heading-title.elementor-size-large{font-size:29px}.elementor-widget-heading .elementor-heading-title.elementor-size-xl{font-size:39px}.elementor-widget-heading .elementor-heading-title.elementor-size-xxl{font-size:59px} James Chalmers: A maverick making an impact in bronchiectasis /*! elementor – v3.22.0 – 26-06-2024 */ …
/*! elementor – v3.21.0 – 26-05-2024 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=”.svg”]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} /*! elementor – v3.21.0 – 26-05-2024 */ .elementor-heading-title{padding:0;margin:0;line-height:1}.elementor-widget-heading .elementor-heading-title[class*=elementor-size-]>a{color:inherit;font-size:inherit;line-height:inherit}.elementor-widget-heading .elementor-heading-title.elementor-size-small{font-size:15px}.elementor-widget-heading .elementor-heading-title.elementor-size-medium{font-size:19px}.elementor-widget-heading .elementor-heading-title.elementor-size-large{font-size:29px}.elementor-widget-heading .elementor-heading-title.elementor-size-xl{font-size:39px}.elementor-widget-heading .elementor-heading-title.elementor-size-xxl{font-size:59px} BIG news for bronchiectasis! …
